p53 as a target for anti-cancer immunotherapy.
The key to specific and non-toxic cancer therapy is likely to be identification and targeting of processes that are absolutely unique to the tumor. One such approach is to target cells expressing mutations in the oncoproteins that led to the development of the cancer, such as p53. In animal model systems, highly mutant p53-specific cytotoxic T cells can be induced, but it remains to be seen whether this can be translated into clinical practice, and what proportion of tumors will respond. In this review, the potential and problems of immunological targeting of mutant p53 in solid tumors are discussed.
Chen
H L
HL
Division of Medical Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Carbone
D P
DP
D000818:Animals; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy*; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D016159:Tumor Suppressor Protein p53